ChemoCentryx Announces Proposed Public Offering of Common Stock
September 26 2018 - 4:01PM
ChemoCentryx, Inc. (Nasdaq:CCXI) announced today that it has
commenced an underwritten public offering of $75 million of its
common stock. In connection with this offering, ChemoCentryx
plans to grant the underwriters a 30-day option to purchase up to
an additional 15 percent of the number of shares sold. J.P.
Morgan and Piper Jaffray & Co. are acting as joint book-running
managers for the offering. All shares of the common stock to be
sold in the offering will be offered by ChemoCentryx. The
offering is subject to market conditions, and there can be no
assurance as to whether or when the offering may be completed, or
as to the actual size or terms of the offering.
The offering will be made by ChemoCentryx pursuant to a
registration statement on Form S-3 previously filed with the
Securities and Exchange Commission (SEC), which became effective on
April 28, 2016. A preliminary prospectus supplement related
to the offering has been filed with the SEC and is available on the
SEC's website located at http://www.sec.gov. Copies of the
preliminary prospectus supplement relating to this offering may be
obtained from: J.P. Morgan Securities LLC, Attention: Broadridge
Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717,
or by telephone at (866) 803-9204, or by email at
prospectus-eq_fi@jpmchase.com; or Piper Jaffray & Co., Attn:
Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, MN
55402, by telephone at (800) 747-3924, or by email at
prospectus@pjc.com.
This press release shall not constitute an offer to sell, or the
solicitation of an offer to buy, nor will there be any sale of,
these securities in any state or other jurisdiction in which such
offer, solicitation or sale would be unlawful prior to the
registration or qualification under the securities laws of such
state or other jurisdiction.
About ChemoCentryx
ChemoCentryx is a biopharmaceutical company developing new
medications targeted at inflammatory and autoimmune diseases and
cancer. ChemoCentryx targets the chemokine and
chemoattractant systems to discover, develop and commercialize
orally-administered therapies.
Forward-Looking Statements
ChemoCentryx cautions you that statements included in this press
release that are not a description of historical facts are
forward-looking statements. Words such as "may," "could,"
"will," "would," "should," "expect," "plan," "anticipate,"
"believe," "estimate," "intend," "predict," "seek," "contemplate,"
"potential," "continue" or "project" or the negative of these terms
or other comparable terminology are intended to identify
forward-looking statements. These statements are based on the
Company's current beliefs and expectations and include the
Company's statements regarding the completion, timing and size of
its offering. The inclusion of forward-looking statements
should not be regarded as a representation by ChemoCentryx that any
of its plans will be achieved. Actual results may differ from
those set forth in this release due to the risks and uncertainties
inherent in the ChemoCentryx business and other risks described in
the Company's filings with the Securities and Exchange Commission
("SEC"). Investors are cautioned not to place undue reliance
on these forward-looking statements, which speak only as of the
date hereof, and ChemoCentryx undertakes no obligation to revise or
update this news release to reflect events or circumstances after
the date hereof. Further information regarding these and
other risks is included under the heading "Risk Factors" in
ChemoCentryx's periodic reports filed with the SEC, including
ChemoCentryx's Annual Report on Form 10-K filed with the SEC on
March 12, 2018 and its other reports which are available from the
SEC's website (www.sec.gov). All forward-looking statements are
qualified in their entirety by this cautionary statement.
This caution is made under the safe harbor provisions of Section
21E of the Private Securities Litigation Reform Act of 1995.
CCXI - G
Contacts:
Susan M. KanayaExecutive Vice President, Chief Financial and
Administrative Officerinvestor@chemocentryx.com
Media:Stephanie Tomei408.234.1279
Investors:Burns McClellan, Inc.Steve
Klass212.213.0006sklass@burnsmc.com
Source: ChemoCentryx, Inc.
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024